Organon & Co. (OGN)

Organon's stock has been impacted by several events in the past six months. In late April 2026, the stock surged due to a proposed acquisition by Sun Pharmaceutical Industries for $11.75 billion, leading to the suspension of financial guidance and cancellation of earnings calls. Organon reported its Q1 2026 earnings on April 30, 2026, with revenue of $1.46 billion and adjusted EPS of $0.71, missing analyst estimates. In February 2026, the stock saw a lift after an independent audit review found no improper conduct regarding biosimilar purchases, but Q4 and full-year 2025 earnings revealed a net loss and flat 2026 guidance.

Demand for Organon's products exhibits some seasonality within its respiratory portfolio, with higher demand for products treating seasonal allergic rhinitis during allergy seasons. Other product categories are primarily driven by factors other than inherent seasonality, such as policy-related demand headwinds in the U.S. for women's health products and generic competition affecting established brands. The biosimilars segment is influenced by new launches and international tenders rather than seasonal demand.

Organon & Co. is a global healthcare company focused on women's health, biosimilars, and established brands. In women's health, Organon offers prescription products for contraception and fertility, including brands like Nexplanon and Puregon. The biosimilars portfolio provides treatments for immunology and oncology, such as Hadlima and Brenzys. Organon's established brands encompass cardiovascular medicines, respiratory products, dermatology products, bone health products, and non-opioid pain management products.

Organon & Co. is headquartered in Jersey City, New Jersey, USA, and its products are available in over 140 countries. The company has a direct footprint in 62 countries and collaborations in more than 80 countries. Approximately 75% of its 2024 revenues were generated outside the United States, with major regions including Europe (25%), Japan and Asia Pacific (25%), and China (15%).

Organon aims to deliver impactful medicines and solutions for a healthier everyday, focusing on women's health. The company has received positive recognition, including being named a "Best Place to Work for Disability Inclusion" and recognized by JUST Capital. However, Organon's reputation was significantly impacted in October 2025 due to an Audit Committee investigation into improper wholesale sales practices for its Nexplanon product, leading to the resignation of the CEO and a drop in the stock price.

Organon & Co.'s ownership is primarily held by institutional investors. As of May 2026, approximately 46.73% of the company's stock is owned by Institutional Investors, 0.33% by Insiders, and 52.94% by Public Companies and Individual Investors. Major institutional shareholders include Vanguard Group Inc., BlackRock, Inc., and State Street Corp.